Distinguishing and Managing Early-Stage Alzheimer’s Disease (AD): Leveraging Interdisciplinary Collaboration for Prompt Identification and Optimal Patient Management
Monday, November 18, 2024
12:00PM – 1:00PM ET
Please note this TeleECHO program is 12:00PM Eastern, 11:00AM Central, 10:00AM Mountain and 9:00AM Pacific.
PRESENTING FACULTY
Barry W. Rovner, MD Professor, Departments of Psychiatry and Neurology Sidney Kimmel Medical College Thomas Jefferson University Philadelphia, PA |
PROGRAM OVERVIEW
This interactive TeleECHO program is designed to provide clinicians who manage patients with Alzheimer’s disease (AD) with up-to-date information on the early diagnosis and treatment in these patients, using strategies to address stigma, apply quantitative assessments, and integrate neuroimaging in clinical assessment; optimal multidisciplinary communication and specialty referral; integration of clinical data updates to inform early identification of AD; and shared decision-making (SDM) approaches with patients and caregivers to facilitate diagnosis and optimize care plans.
TARGET AUDIENCE
This activity is designed to meet the educational needs of healthcare providers (HCPs) involved in the diagnosis and continued care of patients with AD, including neurologists, geriatricians, psychiatrists, primary care physicians, nurses, and other multidisciplinary team members.
LEARNING OBJECTIVES
Learning objectives:
- Implement strategies to overcome barriers to timely diagnosis of Alzheimer’s disease, addressing stigma, applying quantitative assessments, and integrating neuroimaging as well as specialty referral in clinical assessment
- Formulate strategies to optimize multidisciplinary communication and specialty referral
- Incorporate updates in clinical data to inform the identification of AD early in the disease process
- Implement shared decision-making (SDM) approaches to facilitate diagnosis and optimize management
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education (CE) for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
COMMISSION ON DIETETIC REGISTRATION (CDR) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 CPEU.
PHARMACISTS and PHARMACY TECHNICIANS (ACPE) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 knowledge-based CPE contact hours.
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture the faculty may mention the use of medications for both US Food and Drug Administration (FDA)-approved and non-FDA-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]